| 1 |
34748960 | All-in-one nanosponge with pluronic shell for synergistic anticancer therapy through effectively overcoming multidrug resistance in cancer. | 2022 Feb |
2 |
| 2 |
35011550 | Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents. | 2022 Jan 5 |
2 |
| 3 |
35214154 | A Nanosized Codelivery System Based on Intracellular Stimuli-Triggered Dual-Drug Release for Multilevel Chemotherapy Amplification in Drug-Resistant Breast Cancer. | 2022 Feb 15 |
1 |
| 4 |
35533911 | An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2. | 2022 Aug 10 |
1 |
| 5 |
32492505 | Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer. | 2020 Aug 30 |
2 |
| 6 |
32848393 | Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance. | 2020 |
4 |
| 7 |
33299648 | HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model. | 2020 Nov 15 |
2 |
| 8 |
29641982 | Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. | 2018 Jun |
2 |
| 9 |
29995353 | Rational Design of Redox-Responsive and P-gp-Inhibitory Lipid Nanoparticles with High Entrapment of Paclitaxel for Tumor Therapy. | 2018 Sep |
2 |
| 10 |
28947984 | Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. | 2017 Sep 1 |
4 |
| 11 |
29158820 | pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression. | 2017 |
1 |
| 12 |
26586551 | Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. | 2016 Apr |
1 |
| 13 |
25687880 | MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. | 2015 Feb 17 |
1 |
| 14 |
25904021 | Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. | 2015 Oct 15 |
7 |
| 15 |
26474677 | A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. | 2015 Dec 28 |
4 |
| 16 |
24448417 | Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. | 2014 Apr |
3 |
| 17 |
24781280 | Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. | 2014 May 27 |
2 |
| 18 |
24786296 | ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo. | 2014 Aug |
1 |
| 19 |
24952376 | 4,5-Di-substituted benzyl-imidazol-2-substituted amines as the structure template for the design and synthesis of reversal agents against P-gp-mediated multidrug resistance breast cancer cells. | 2014 Aug 18 |
1 |
| 20 |
24954663 | Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. | 2014 Sep 10 |
3 |
| 21 |
24956463 | A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors. | 2014 Oct 1 |
21 |
| 22 |
25093335 | A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells. | 2014 |
1 |
| 23 |
23090875 | P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. | 2013 May 15 |
1 |
| 24 |
23838193 | Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. | 2013 Nov 1 |
1 |
| 25 |
23022332 | Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. | 2012 Dec 5 |
2 |
| 26 |
22036081 | Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect. | 2011 Dec 2 |
1 |
| 27 |
19800114 | The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. | 2010 Jan |
2 |
| 28 |
19924122 | Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. | 2010 Jan |
2 |
| 29 |
20845461 | Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. | 2010 Nov |
1 |
| 30 |
19821097 | Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo. | 2009 Oct |
1 |
| 31 |
17932689 | Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. | 2008 May |
3 |
| 32 |
18813783 | Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors. | 2008 Oct |
1 |
| 33 |
17242698 | Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. | 2007 Jan 29 |
2 |
| 34 |
17062689 | Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. | 2006 Oct 15 |
5 |
| 35 |
15378273 | Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. | 2005 Jan |
3 |
| 36 |
14605863 | The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. | 2004 Feb |
1 |
| 37 |
15322237 | P-glycoprotein mediates resistance to histidine kinase inhibitors. | 2004 Sep |
1 |
| 38 |
15514563 | Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel. | 2004 Nov |
1 |
| 39 |
15663292 | Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. | 2004 |
2 |
| 40 |
12824894 | DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. | 2003 May |
1 |
| 41 |
12855665 | Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. | 2003 Jul |
2 |
| 42 |
12941842 | The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. | 2003 Aug 15 |
2 |
| 43 |
11914641 | Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. | 2002 Jan |
2 |
| 44 |
12417570 | Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. | 2002 Nov |
4 |
| 45 |
12438532 | Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. | 2002 Dec |
1 |
| 46 |
11172691 | Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. | 2001 Jan |
1 |
| 47 |
11707575 | Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. | 2001 Nov 20 |
10 |
| 48 |
10773541 | Assessment of resistance to paclitaxel of murine tumors by (99m)Tc-MIBI/(201)Tl dual-radionuclide imaging. | 2000 Feb |
1 |
| 49 |
11059771 | Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. | 2000 Oct 15 |
1 |
| 50 |
11102737 | Modulation of oral bioavailability of anticancer drugs: from mouse to man. | 2000 Dec |
2 |